anti-IGF-BP3 antibody product blog
Tags: Antibody; Monoclonal Antibody; IGF-BP3; anti-IGF-BP3 antibody;
The IGF-BP3 igfbp3 (Catalog #MBS690531) is an Antibody produced from Rat and is intended for research purposes only. The product is available for immediate purchase. The Rat Anti-Mouse IGF-BP3 reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s IGF-BP3 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB).1. Western blot (Non-reducing samples): Yes (1:500-1000). Researchers should empirically determine the suitability of the IGF-BP3 igfbp3 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The IGF-BP3 igfbp3 product has the following accession number(s) (GI #111378400) (NCBI Accession #NP_032369.2) (Uniprot Accession #P47878). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.
Antibody Generation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a rat immunized with purified mouse recombinant protein of IGF-BP3. The IgG2 fraction of the culture supernatant was purified by Protein A/G affinity chromatography. Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing IGF-BP3 are readily searchable from our website. Different antibodies against the same target such as IGF-BP3 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Adenocarcinoma, Breast Neoplasms, Cardiovascular Diseases, Colorectal Neoplasms, Inflammation, Kidney Diseases, Liver Diseases, Neoplasms, Prostatic Neoplasms, Weight Gain are some of the diseases may be linked to Rat Anti-Mouse IGF-BP3. Bone, Brain, Heart, Kidney, Liver, Lung, Other, Ovary, Skin, Thyroid tissues are correlated with this protein. The following patways have been known to be associated with this gene.